These findings underline once again the importance to refer patients with KIT/PDGFRA WT GIST to high-volume molecular diagnostic centers as already also suggested by the recent clinical guidelines (26), in which the implementation of appropriate next-generation-sequencing panels could be used to address the few cases with cryptic KIT mutations. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.